Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma, Non-Hodgkin
In brief
Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally. Incidence and mortality rates from NHL are highest in developed countries. While many patients with aggressive NHL are curable with initial anthracycline-containing regimens, the majority of patients will relapse or prove refractory to initial therapy. The prognosis of patients with disease recurrence following a multidrug regimen is also limited. The current protocol is designed to test the safety and efficacy of BAY 59-8862 in patients with Aggressive Refractory Non-Hodgkin's Lymphoma.
Key facts
- Study ID
- NCT00044551
- Run by
- Bayer
- People needed
- 29
- Starts
- 2002-02-01
- Expected to finish
- 2003-07-01
- Last updated by the study team
- 2013-10-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Miami Beach, Florida, United States
- Study site — Chicago, Illinois, United States
- Study site — Shreveport, Louisiana, United States
- Study site — New Brunswick, New Jersey, United States
- Study site — Brooklyn, New York, United States
- Study site — Manhasset, New York, United States
- Study site — Syracuse, New York, United States
- Study site — The Bronx, New York, United States
- Study site — Valhalla, New York, United States
- Study site — Cleveland, Ohio, United States
- Study site — Memphis, Tennessee, United States
- Study site — Seattle, Washington, United States
- Study site — Milwaukee, Wisconsin, United States
- Study site — Edmonton, Alberta, Canada
- Study site — Paris, France
- Study site — Pierre-Bénite, France
- Study site — Vandœuvre-lès-Nancy, France
- Study site — Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Study site — Berlin, State of Berlin, Germany
- Study site — Amsterdam, Netherlands
- Study site — Groene Hilledijk, Netherlands
- Study site — Cambridge, Cambridgeshire, United Kingdom
- Study site — Maidstone, Kent, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.